Pulmonary Hypertension, Systemic Sclerosis
Conditions
Brief summary
Exercise-induced increase of the pulmonary arterial pressure may be an early sign of pulmonary arterial hypertension. It has been shown that patients with normal pulmonary arterial pressure at rest but elevated pulmonary arterial pressure during exercise have a decreased exercise-capacity and may have a worse prognosis compared to patients with normal pulmonary arterial pressure values at rest and during exercise. According to the currently used definition pulmonary hypertension can be diagnosed if the mean pulmonary arterial pressure is higher than 25mmHg at rest or 30mmHg during exercise. In this study patients with a risk for pulmonary arterial hypertension (connective tissue disease) and increased pulmonary arterial pressure values during exercise are receiving a therapy with a dual endothelin receptor antagonist - bosentan, a therapy established for pulmonary arterial hypertension. The therapy effect is than compared to the recorded changes before the introduction of this therapy.
Detailed description
Bosentan is an established therapy in pulmonary arterial hypertension, which may be diagnosed when the mean pulmonary arterial pressure is \>25mmHg at rest or \>30mmHg at exercise. Bosentan has shown efficacy, if mean pulmonary arterial pressure was elevated at rest. However, there are no data available of the effects of such a therapy, if the mean pulmonary arterial pressure is normal at rest but elevated during exercise. The purpose of this study is to provide additional data on this group of patients. Our hypothesis is that patients with exercise-induced pulmonary hypertension may show a gradual worsening of pulmonary hemodynamics and potentially a development of manifest pulmonary arterial hypertension (elevated resting pulmonary arterial pressure values) without treatment, while the introduction of Bosentan may improve hemodynamics and exercise capacity in this patient group.
Interventions
DRUGBosentan
2x62.5mg for 4 weeks, then 2x125mg
Sponsors
Actelion
Medical University of Graz
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* exercise-induced pulmonary hypertension * systemic sclerosis
Exclusion criteria
* relevant pulmonary obstruction or restriction * relevant left cardiac disease * recent changes in medical therapy * recent major operations * recent major cardiovascular diseases * inability to perform exercise
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of mean pulmonary arterial pressure at 50W under therapy with Bosentan compared to change of mean pulmonary arterial pressure at 50W before the introduction of therapy with Bosentan | 12months before Bosentan therapy vs. at begin of bosentan therapy vs. 6months under bosentan therapy |
Secondary
| Measure | Time frame |
|---|---|
| pulmonary vascular resistance, peak oxygen uptake | 12months before Bosentan therapy vs. at begin of bosentan therapy vs. 6months under bosentan therapy |
Countries
Austria
Outcome results
None listed